Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XNW5004 vs Chidamide in relapsed/refractory peripheral T-cell lymphoma
NCT06776952Phase 3Recruiting
- Sponsor
- Evopoint Biosciences
- Start
- Apr 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of igermetostat in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by Evopoint Biosciences. Primary endpoint: Progression-Free Survival at 24 months. Started Apr 2025; status: recruiting.
02
Drugs
igermetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06776952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06776952.